An insurance company has denounced the reorganization plan of Pfizer Inc. subsidiary Quigley Co. Inc. as little more than a ploy to protect the drugmaker from liability for asbestos claims leveled at its defunct subsidiary.
The first trial in the multidistrict legislation over Novartis Pharmaceuticals Corp.'s bone cancer drugs Aredia and Zometa is drawing closer, now that both sides have selected 10 bellwether cases for the first round of trials.
The multidistrict litigation over Eli Lilly & Co.'s anti-psychotic drug Zyprexa is “fundamentally different” from the ongoing putative class action over the drug industry's average wholesale prices, and a decision in that case should not influence Lilly's case, Lilly's lawyers told the MDL judge Thursday.
Wilson Sonsini Goodrich & Rosati PC has brought on Mylan Inc.'s former chief legal officer, Stuart A. Williams, to bolster the firm's interdisciplinary global generics practice.
Pfizer Inc.'s anti-smoking drug Chantix, which is already subject to U.S. Food and Drug Administration warnings for increased risk of depression and suicide, may be linked to heart rhythm disturbances, seizures and loss of consciousness, a new report suggests.
The Delaware Chancery Court has handed billionaire activist investor Carl Icahn a victory in his tussle with Biogen Idec Inc., ordering the biotechnology company to hand over material regarding an unsuccessful sale attempt last year.
Two former employees who lodged a 2005 qui tam complaint against Kyphon Inc., which was since bought by Medtronic Inc., are in line to collect $14.9 million of a $75 million settlement in a suit that alleged Kyphon caused the submission of false or fraudulent claims to Medicare.
Medtronic Inc. will pay $75 million plus interest to settle a False Claims Act suit that accused Kyphon Inc. (which Medtronic bought in November) of engaging in a seven-year scheme that led to Medicare paying for inpatient spinal surgeries as opposed to less costly outpatient treatments.
Houghton Mifflin Harcourt Publishing Co., Baxter Healthcare Corp. and Eastman Kodak Co. were just some of the companies that hired law firms to work on major IP litigation in recent weeks, according to our daily review of court dockets.
Baxter Healthcare Corp. is suing Talecris Biotherapeutics Inc. for allegedly infringing three of Baxter's patents on methods of testing blood for infection.
Patent settlements in which drugmakers pay their generics rivals to keep generic competition off the market may stifle competition, according to a report from the U.S. Federal Trade Commission released on Tuesday.
Citing European patent law precedents, a U.K. appellate court has reversed a lower court order revoking Merck & Co. Inc.'s patent for male pattern baldness treatment Propecia, finding that Actavis UK Ltd.'s challenge was an “unusual case” in which a change of dosage for a drug was patentable.
Johnson & Johnson, Epson America Inc. and Cox Communications Inc. were just some of the companies that hired law firms to work on major IP litigation in recent weeks, according to our daily review of court dockets.
Two members of the U.S. House of Representatives have asked four major drug companies to adopt practices aimed at reducing deceptive and misleading direct-to-consumer advertisements.
The Fosamax plaintiffs have demanded that Merck & Co. turn over a slew of documents, a request that the pharmaceutical giant has balked at as the multidistrict litigation over whether the osteoporosis drug leads to a painful deterioration of the jaw continues to move toward trial.
In a setback for Bausch & Lomb Inc., a federal judge has stayed the eye-care company's infringement suit related to a visual nutritional supplement pending a regulatory re-examination of the asserted patent, barring the defendants from marketing the offending product in the interim.
A federal bankruptcy judge has cut Pfizer Inc. a break in its subsidiary Quigley Co. Inc.'s bankruptcy case, ruling that an injunction against asbestos-related litigation still stands even though it was amended in December 2007.
An appeals court has upheld a ruling requiring Fresenius Medical Care to turn over documents related to the company's billing procedures for Epogen in the government's continuing probe into Medicare fraud associated with the drug.
The Minnesota plaintiffs in the Mirapex product liability litigation have taken advantage of a ruling that gave them the green light to demand punitive damages, filing an amended complaint in their ongoing case against several major drugmakers.
Wyeth Pharmaceuticals Inc. and Nycomed GmbH have moved again to protect a patent for their injectable heartburn treatment Protonix, launching a lawsuit against a unit of Novartis AG that plans a copycat version of the drug.